Talking about what others are afraid to say
After some great feedback, I realize that I may have published a post that was misunderstood. Some readers have misinterpreted my message. I never intended to suggest that Medical Affairs …
Medical Affairs and Commercialization: Collaboration Is Essential, but Boundaries Matter Read More
It’s been a good week for Bristol Myers Squibb, and it deserves to enjoy it. On October 12, the company said an experimental radiation drug called RYZ101 slowed the growth …
BMS Has a Promising Cancer Drug. Now It Has to Get Out of Its Own Way. Read More
Does DTC marketing really work, and are physicians turning to AI instead of relying on MSL’s? Those are two huge questions that every pharma company faces. It depends on the …
Pharma Marketing: The Rise of AI and Patient Trust Read More
Ask any pharma executive about their talent problem, and you’ll hear about scientists. Chemists, biologists, clinical trial experts. The people who discover and develop the drugs. And yes, that pipeline …
Pharma Has a Talent Problem, and It Isn’t the One You Think Read More
A month and a half after Revolution Medicines launched its pancreatic cancer pill, I keep running into the same two thoughts. The drug is a real breakthrough. And some of …
Rasonque Is About to Face Competition. Did They Overestimate Their Sales Forecast? Read More
Healthcare marketing has become obsessed with data, metrics, and meetings. Somewhere along the way, I worry we’ve forgotten who we’re supposed to help.
After 21 Years in Healthcare Marketing, I Have Something I Want to Say Read More
FDA clearance, a big raise, and interesting science are not a commercial strategy. The medical device industry has a habit it won’t admit to: confusing a good invention with a …
Why FDA Clearance Alone Can’t Guarantee Medical Device Success Read More
Imagine you run benefits for a mid-sized company. Every month, a pharmacy benefit manager (PBM) bills you for your employees’ prescriptions. You trust the number because you have no real …
What Happens When You Reprice a Dozen Employers’ Prescription Claims at Cost Plus Drugs? Read More